89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
89bio's Pegozafermin Is Now Gaining Momentum
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
89bio, Inc. (NASDAQ:ETNB) Receives $30.33 Average Target Price from Analysts
Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...
Yahoo Finance4d
89bio, Inc. (ETNB)
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...
BioPharma Dive1d
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Investors Buy Large Volume of Call Options on 89bio (NASDAQ:ETNB)
Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
ENDPOINTS NEWS3d
Akero, 89bio dis­close pub­lic of­fer­ings; BioAge drops Phase 2 obe­si­ty drug
For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering ...
Investor's Business Daily on MSN3d
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study
Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...